These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27575698)

  • 41. Antimicrobial susceptibility and molecular characteristics of methicillin-resistant Staphylococcus aureus in a Japanese secondary care facility.
    Kimura Y; Morinaga Y; Akamatsu N; Matsuda J; Yamaryo T; Kawakami K; Matsuo H; Kosai K; Uno N; Hasegawa H; Yanagihara K
    J Infect Chemother; 2016 Jan; 22(1):14-8. PubMed ID: 26617349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.
    Takata T; Miyazaki M; Futo M; Hara S; Shiotsuka S; Kamimura H; Yoshimura H; Matsunaga A; Nishida T; Ishikura H; Ishikawa T; Tamura K; Tsuji BT
    Scand J Infect Dis; 2013 Mar; 45(3):203-12. PubMed ID: 23113753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Emergence of vancomycin-intermediate Staphylococcus aureus from predominant methicillin-resistant S. aureus clones in a Korean hospital.
    Cha HY; Kim HO; Jin JS; Lee JC
    J Microbiol; 2010 Aug; 48(4):533-5. PubMed ID: 20799097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.
    Mendes RE; Sader HS; Deshpande LM; Diep BA; Chambers HF; Jones RN
    J Clin Microbiol; 2010 Feb; 48(2):568-74. PubMed ID: 19940054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Infectivity-resistotype-genotype clustering of methicillin-resistant Staphylococcus aureus strains in the Central Blacksea Region of Turkey].
    Kırca Yılmaz S; Acuner IC; Strommenger B; Bek Y; Witte W
    Mikrobiyol Bul; 2014 Jan; 48(1):14-27. PubMed ID: 24506712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of Staphylococcus aureus faecal isolates associated with food-borne disease in Korea.
    Shin E; Hong H; Park J; Oh Y; Jung J; Lee Y
    J Appl Microbiol; 2016 Jul; 121(1):277-86. PubMed ID: 26991816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.
    Wang JL; Wang JT; Sheng WH; Chen YC; Chang SC
    BMC Infect Dis; 2010 Jun; 10():159. PubMed ID: 20529302
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigation of heteroresistant vancomycin intermediate Staphylococcus aureus among MRSA isolates.
    Gazel D; Erinmez M; Büyüktaş Manay A; Zer Y
    J Infect Dev Ctries; 2021 Jan; 15(1):89-94. PubMed ID: 33571150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital.
    Panomket P; Thirat S; Wanram S; Sranujit RP
    J Med Assoc Thai; 2014 Apr; 97 Suppl 4():S7-11. PubMed ID: 24851558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041.
    Monaco M; Sanchini A; Grundmann H; Pantosti A;
    Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):771-7. PubMed ID: 20401508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genotype diversity of methicillin-resistant Staphylococcus aureus in Shenyang, China.
    Tian SF; Chu YZ; Nian H; Li FS; Sun JM; Wang YL; Liu LW; Shang H
    Scand J Infect Dis; 2013 Dec; 45(12):915-21. PubMed ID: 24032434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced vancomycin susceptibility and increased macrophage survival in Staphylococcus aureus strains sequentially isolated from a bacteraemic patient during a short course of antibiotic therapy.
    Basco MDS; Kothari A; McKinzie PB; Revollo JR; Agnihothram S; Azevedo MP; Saccente M; Hart ME
    J Med Microbiol; 2019 Jun; 68(6):848-859. PubMed ID: 31136294
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High frequency of multidrug-resistant Staphylococcus aureus with SCCmec type III and Spa types t037 and t631 isolated from burn patients in southwest of Iran.
    Parhizgari N; Khoramrooz SS; Malek Hosseini SA; Marashifard M; Yazdanpanah M; Emaneini M; Gharibpour F; Mirzaii M; Darban-Sarokhalil D; Moein M; Naraki M
    APMIS; 2016 Mar; 124(3):221-8. PubMed ID: 26709106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials.
    Hos NJ; Jazmati N; Stefanik D; Hellmich M; AlSael H; Kern WV; Rieg S; Wisplinghoff H; Seifert H; Kaasch AJ
    J Infect; 2017 Mar; 74(3):248-259. PubMed ID: 28017826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences between "classical" risk factors for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and risk factors for nosocomial bloodstream infections caused by multiple clones of the staphylococcal cassette chromosome mec type IV MRSA strain.
    Vidal PM; Trindade PA; Garcia TO; Pacheco RL; Costa SF; Reinert C; Hiramatsu K; Mamizuka EM; Garcia CP; Levin AS
    Infect Control Hosp Epidemiol; 2009 Feb; 30(2):139-45. PubMed ID: 19146463
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and molecular characteristics of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern China.
    Cheng X; Ma L; Wang Y; Sun W; Su J
    Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116180. PubMed ID: 38183897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.